Status:
RECRUITING
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer
Lead Sponsor:
Huashan Hospital
Conditions:
Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[131I\]/\[18F\]/\[68Ga\]ZT-111 in patients with PSMA positive metastatic prostate cancer.
Eligibility Criteria
Inclusion
- Age between 18 and 65 years old.
- Histologically or cytologically confirmed prostate adenocarcinoma with documented history of ≥1 metastatic lesions indicated by imaging.
- Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver.
- Willing and able to comply with all aspects of this study.
Exclusion
- Severe hepatic or renal impairment.
- History of major surgery within the last month.
- Participation in another concurrent clinical trial.
Key Trial Info
Start Date :
December 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06201741
Start Date
December 27 2023
End Date
June 30 2024
Last Update
January 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, China